Oppenheimer analyst Suraj Kalia maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $240 to $270.
Oppenheimer Maintains Outperform on ResMed, Raises Price Target to $270
Oppenheimer analyst Suraj Kalia maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $240 to $270.
Related Posts
Hoth Therapeutics Announces Pipeline Presentation At The 2022 Bio International Convention
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the company will be presenting at the BIO International Convention taking place June 13 - 16,
Credit Suisse Maintains Outperform on Texas Roadhouse, Lowers Price Target to $115
Credit Suisse analyst Lauren Silberman maintains Texas Roadhouse (NASDAQ:TXRH) with a Outperform and lowers the price target from $118 to $115.
How To Trade Starbucks Stock Before And After Q3 Earnings
Starbucks Corporation (NASDAQ: SBUX) shot up briefly intraday before retracing under Monday’s low-of-day to head into its third-quarter financial results Tuesday afternoon.